1. Home
  2. CRDF vs MTA Comparison

CRDF vs MTA Comparison

Compare CRDF & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • MTA
  • Stock Information
  • Founded
  • CRDF 1999
  • MTA 1983
  • Country
  • CRDF United States
  • MTA Canada
  • Employees
  • CRDF N/A
  • MTA N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • MTA
  • Sector
  • CRDF Health Care
  • MTA
  • Exchange
  • CRDF Nasdaq
  • MTA Nasdaq
  • Market Cap
  • CRDF 288.7M
  • MTA 267.2M
  • IPO Year
  • CRDF N/A
  • MTA N/A
  • Fundamental
  • Price
  • CRDF $3.73
  • MTA $3.08
  • Analyst Decision
  • CRDF Strong Buy
  • MTA Hold
  • Analyst Count
  • CRDF 4
  • MTA 1
  • Target Price
  • CRDF $12.00
  • MTA $4.50
  • AVG Volume (30 Days)
  • CRDF 1.2M
  • MTA 371.4K
  • Earning Date
  • CRDF 05-01-2025
  • MTA 05-14-2025
  • Dividend Yield
  • CRDF N/A
  • MTA N/A
  • EPS Growth
  • CRDF N/A
  • MTA N/A
  • EPS
  • CRDF N/A
  • MTA N/A
  • Revenue
  • CRDF $683,000.00
  • MTA $5,048,000.00
  • Revenue This Year
  • CRDF N/A
  • MTA $37.69
  • Revenue Next Year
  • CRDF N/A
  • MTA $120.61
  • P/E Ratio
  • CRDF N/A
  • MTA N/A
  • Revenue Growth
  • CRDF 39.96
  • MTA 28.55
  • 52 Week Low
  • CRDF $2.01
  • MTA $2.32
  • 52 Week High
  • CRDF $6.42
  • MTA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 45.87
  • MTA 54.87
  • Support Level
  • CRDF $3.65
  • MTA $2.93
  • Resistance Level
  • CRDF $3.88
  • MTA $3.17
  • Average True Range (ATR)
  • CRDF 0.26
  • MTA 0.14
  • MACD
  • CRDF -0.02
  • MTA 0.02
  • Stochastic Oscillator
  • CRDF 30.00
  • MTA 73.04

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

Share on Social Networks: